Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.

ABSTRACT:

Background

The purpose of this study was to estimate the annual and per-patient budget impact of the treatment of moderate to severe psoriasis in Greece before and after the introduction of ustekinumab.

Methods

A budget impact model was constructed from a national health system perspective to depict the clinical and economic aspects of psoriasis treatment over 5 years. The model included drug acquisition, monitoring, and administration costs for both the induction and maintenance years for patients in a treatment mix with etanercept, adalimumab, infliximab, with or without ustekinumab. It also considered the resource utilization for non-responders. Greek treatment patterns and resource utilization data were derived from 110 interviews with dermatologists conducted in Februar

SUBMITTER: Avgerinou G 

PROVIDER: S-EPMC3420305 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature